Jasper B.

Excision BioTherapeutics is a private company focused on developing advanced gene editing therapeutics to address the medical need for the treatment of life-threatening disease caused by viral infections. Our mission is to advance gene editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.

MAIA Biotechnology is a targeted therapy, immune-oncology company, focused on development and commercialization of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. A publicly traded company based in Chicago, MAIA (NYSE American: MAIA) is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into human clinical trials. MAIA’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. MAIA controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. MAIA’s business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure.

A rocket company at the core, Relativity Space is on a mission to become the next great commercial launch company. With an ever-growing need for space infrastructure, demand for launch services is continuously outpacing supply. Our reusable rockets can meet this demand, offering customers the right size payload capacity at the right cost. Leveraging advances in additive manufacturing, we are strategically focused on reducing vehicle complexity, cost, and time to market. Our patented technologies enable innovative designs once thought impossible and unlock new value propositions in the booming space economy.

Excision BioTherapeutics is a private company focused on developing advanced gene editing therapeutics to address the medical need for the treatment of life-threatening disease caused by viral infections. Our mission is to advance gene editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.

MAIA Biotechnology is a targeted therapy, immune-oncology company, focused on development and commercialization of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. A publicly traded company based in Chicago, MAIA (NYSE American: MAIA) is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into human clinical trials. MAIA’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. MAIA controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. MAIA’s business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure.

A rocket company at the core, Relativity Space is on a mission to become the next great commercial launch company. With an ever-growing need for space infrastructure, demand for launch services is continuously outpacing supply. Our reusable rockets can meet this demand, offering customers the right size payload capacity at the right cost. Leveraging advances in additive manufacturing, we are strategically focused on reducing vehicle complexity, cost, and time to market. Our patented technologies enable innovative designs once thought impossible and unlock new value propositions in the booming space economy.

The traditional gatekeepers of capital are no longer the issue to funding your project, but finding a partner that can meaningfully add value to your team and project is. Cluster is a distributed network of crypto insiders, influencers, builders, and investors. We provide the support, connections and traction your project needs to truly succeed.